PYRAMID and LYM2034: Targeted randomized phase II studies of bortezomib with or without immunochemotherapy in newly diagnosed nongerminal center B-cell-like (GCB) diffuse large B-cell lymphoma (DLBCL), including rapid prospective non-GCB subtype identification.

Authors

J. Leonard

Weill Cornell Medical College, New York, NY

J. Leonard , J. Reeves , B. Ferhanoglu , K. T. Doner , H. Eom , I. W. Flinn , J. Raposo , N. M. Chowhan , C. Suh , S. Noga , G. Tumyan , S. Aung , J. Hajdenberg , B. K. Ulrich , K. B. Pendergrass , G. Mulligan , A. Rizo , S. Kussick , F. Offner

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Long-term outcomes and circulating tumor DNA analysis from a phase I/II study of lenalidomide and obinutuzumab with CHOP for newly diagnosed diffuse large B-cell lymphoma.

First Author: Hua-Jay Jeffery Cherng

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

waveLINE-007: Phase 2 study of zilovertamab vedotin (ZV) in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab (R-CHP) in previously untreated diffuse large B-cell lymphoma (DLBCL).

First Author: David Lavie

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Evaluation of outcomes between rituximab-abbs and reference product rituximab in adult patients with newly diagnosed diffuse large B-cell lymphoma in a non-inferiority study.

First Author: Vivian Nguyen

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

A randomized, double-blind, placebo-controlled phase 3 study of ibrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in subjects with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell lymphoma (DLBCL).

First Author: Anas Younes